DrugPatentWatch Database Preview
ISRADIPINE Drug Profile
see a sample report or, see our see our flat-rate plans
When do Isradipine patents expire, and when can generic versions of Isradipine launch?
The generic ingredient in ISRADIPINE is isradipine. There are seven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the isradipine profile page.
Summary for ISRADIPINE
| US Patents: | 0 |
| Applicants: | 3 |
| NDAs: | 3 |
| Suppliers / Packagers: | 5 |
| Bulk Api Vendors: | 69 |
| Clinical Trials: | 8 |
| Patent Applications: | 4,485 |
| Formulation / Manufacturing: | see details |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ISRADIPINE |
| DailyMed Link: | ISRADIPINE at DailyMed |
Pharmacology for ISRADIPINE
| Ingredient-type | Dihydropyridines |
| Drug Class | Dihydropyridine Calcium Channel Blocker |
| Mechanism of Action | Calcium Channel Antagonists |
Medical Subject Heading (MeSH) Categories for ISRADIPINE
Synonyms for ISRADIPINE
| (-)-Isradipine |
| (.+/-.)-Isradipine |
| (+-)-Isradipine |
| (+)-isradipine |
| (+/-)-Isradipine |
| (non-Isotopelabelled)Isradipine-d7 |
| (plusmn)-isradipine |
| 131970-21-3 |
| 2,1,3-Benzoxadiazole, 3,5-pyridinedicarboxylic acid deriv. |
| 3-Isopropyl 5-methyl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydro-3,5-pyridinedicarboxylate # |
| 3-isopropyl 5-methyl 4-(benzo[c][1,2,5]oxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate |
| 3-methyl 5-propan-2-yl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate |
| 3-O-methyl 5-O-propan-2-yl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate |
| 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-(4-benzofurazanyl)-2,6-dimethyl-, methyl 1-methylethyl ester, (+-)- |
| 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-(4-benzofurazanyl)-2,6-dimethyl-,methyl 1-methylethyl ester, (+-)- |
| 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, 3-methyl 5-(1-methylethyl) ester |
| 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester |
| 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester (9CI) |
| 3,5-Pyridinedicarboxylic acid, 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester |
| 3,5-Pyridinedicarboxylic acid, 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester, (.+/-.)- |
| 3,5-Pyridinedicarboxylic acid, 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester, (+-)- |
| 4-(2,1,3-Benzooxadiazol-4-yl)-2.6-dimethyl-1,4-dihydro-3-isopropyloxycarbonylpyridine-5-carboxylic Acid Methyl Ester |
| 4-(2,1,3-Benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinecarboxylic acid methyl 1-methylethyl ester |
| 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid O3-methyl ester O5-propan-2-yl ester |
| 4-(4-Benzofurazanyl)-1,-4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methhylethyl ester |
| 4-(4-Benzofurazanyl)-1,-4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester |
| 4-(4-Benzofurazanyl)-1,4-dihydro-2,-6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester |
| 4-(4-Benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic Acid Isopropyl Methyl Ester |
| 4-(4-Benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester |
| 695I931 |
| 75695-93-1 |
| 88977-22-4 |
| AB00514007 |
| AB00514007_02 |
| AB00514007_03 |
| AB2000202 |
| AC-8539 |
| AC1L1GPE |
| AC1Q426L |
| ACM131970213 |
| ACT02697 |
| AK163124 |
| AKOS015895129 |
| AN-7921 |
| Antiviral (genital herpes), PharmaNova |
| AOB5974 |
| API0003052 |
| BDBM50436176 |
| BG0371 |
| BPBio1_001323 |
| BRD-A90799790-001-03-3 |
| BSPBio_001201 |
| C19H21N3O5 |
| CAS-75695-93-1 |
| CCG-101027 |
| CCG-213711 |
| CHEBI:6073 |
| CHEBI:91953 |
| CHEMBL1648 |
| CHEMBL315436 |
| CHEMBL3211306 |
| CI0041 |
| Clivoten |
| CPD002529690 |
| CS-2201 |
| CTK8G0407 |
| D00349 |
| D0HC8Q |
| D0Z7KE |
| DB00270 |
| DR002052 |
| DSSTox_CID_3179 |
| DSSTox_GSID_23179 |
| DSSTox_RID_76907 |
| DTXSID4023179 |
| DynaCirc |
| DynaCirc (TN) |
| Dynacirc CR |
| DynaCirc, Prescal, PN-200-110, Clivoten, Esradin, Isradipine |
| DynaCirc;Prescal;PN-200-110;Clivoten;Esradin;Dynacirc |
| DynaCire |
| DynaCire CR |
| Dynacrine |
| Esradin |
| FT-0627542 |
| GTPL4488 |
| HE386320 |
| HMJIYCCIJYRONP-UHFFFAOYSA-N |
| HMS1571M03 |
| HMS2051J12 |
| HMS2098M03 |
| HMS2235O12 |
| HMS3268D21 |
| HMS3393J12 |
| HMS3655C17 |
| HS-0085 |
| HY-B0233 |
| I06-0364 |
| I0876 |
| Icaz |
| isopropyl 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-3-pyridinecarboxylate |
| Isopropyl methyl (.+/-.)-4-(4-benzfurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate |
| Isopropyl methyl (.+/-.)-4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate |
| Isopropyl methyl (+-)-4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate |
| Isopropyl Methyl 4-(2,1,3-Benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimet |
| Isopropyl Methyl 4-(4-Benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate |
| Isradipin |
| Isradipine (Dynacirc) |
| Isradipine (USP/INN) |
| Isradipine [USAN:INN:BAN] |
| Isradipine [USAN:USP:INN:BAN] |
| Isradipine, (+-)-Isomer |
| Isradipine, (R)-Isomer |
| Isradipine, (S)-Isomer |
| Isradipine, >=98% (HPLC), solid |
| Isradipine, European Pharmacopoeia (EP) Reference Standard |
| Isradipine, United States Pharmacopeia (USP) Reference Standard |
| Isradipine(Dynacirc) |
| Isradipino |
| Isradipino [Spanish] |
| Isradipinum |
| Isradipinum [Latin] |
| Isrodipine |
| J-513454 |
| K297 |
| KBio2_000698 |
| KBio2_003266 |
| KBio2_005834 |
| KBioSS_000698 |
| KS-0000118G |
| Lomir |
| LS-131190 |
| LS-177211 |
| methyl 1-methylethyl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate |
| MFCD00153820 |
| MLS000759425 |
| MLS001424076 |
| MLS002154106 |
| MLS003915633 |
| MLS006010138 |
| MolPort-003-848-292 |
| NC00277 |
| NCGC00016931-01 |
| NCGC00025341-01 |
| NCGC00025341-02 |
| NCGC00025341-03 |
| NCGC00025341-06 |
| NSC-759892 |
| NSC759892 |
| O5-isopropyl O3-methyl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate |
| O5-methyl O3-propan-2-yl 4-(2,1,3-benzoxadiazol-7-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate |
| Pharmakon1600-02300234 |
| PN 200 |
| PN 200-110 |
| PN 205 033 |
| PN 205 034 |
| PN 205-033 |
| PN 205-034 |
| PN 205033 |
| PN 205034 |
| PN-200 |
| PN-200-110 |
| PN-200, PharmaNova |
| PN-200110 |
| PN-205-033 |
| PN-205-034 |
| PN205033 |
| PN205034 |
| Prescal |
| Prescal (TN) |
| Prestwick0_001021 |
| Prestwick1_001021 |
| Prestwick2_001021 |
| Prestwick3_001021 |
| Rebriden |
| RL04885 |
| s1662 |
| SAM001246584 |
| SC-16999 |
| SCHEMBL34555 |
| SMR000466320 |
| SMR002529690 |
| SPBio_003062 |
| Spectrum_000218 |
| SR-01000597526 |
| SR-01000597526-2 |
| Tox21_110690 |
| Tox21_110690_1 |
| VA11116 |
US Patents and Regulatory Information for ISRADIPINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elite Labs Inc | ISRADIPINE | isradipine | CAPSULE;ORAL | 077169-001 | Apr 24, 2006 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Watson Labs Teva | ISRADIPINE | isradipine | CAPSULE;ORAL | 077317-002 | Jan 5, 2006 | AB | RX | No | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Elite Labs Inc | ISRADIPINE | isradipine | CAPSULE;ORAL | 077169-002 | Apr 24, 2006 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Watson Labs Teva | ISRADIPINE | isradipine | CAPSULE;ORAL | 077317-001 | Jan 5, 2006 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
see a sample report or, see our see our flat-rate plans
